D-0251-2026 Class II Ongoing
FDA drug recall D-0251-2026 was initiated by Imprimis NJOF, LLC on Dec 18, 2025 and is designated Class II. Reason for recall: Presence of particulate matter - Glass like particles. The recall status is ongoing. Affected quantity: 314 boxes of 6,280 pre-filled syringes.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 14, 2026
- Initiation Date
- Dec 18, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 314 boxes of 6,280 pre-filled syringes
Product description
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Reason for recall
Presence of particulate matter - Glass like particles.
Distribution pattern
U.S Nationwide
Code information
Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0251-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026